We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NAVB market cap is 9.98k. The company's latest EPS is USD -0.1724 and P/E is -0.46.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.17M | 658k | 915k | 532k | 66k |
| Operating Income | -10.85M | -10.96M | -10.71M | -12.06M | -14.05M |
| Net Income | -16.11M | -10.95M | -11.39M | -11.73M | -17.22M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 7.02M | 4.15M | 7.76M | 6.65M | 4.37M |
| Total Liabilities | 4.61M | 5.03M | 5.71M | 6.02M | 12.52M |
| Total Equity | 2.41M | -881k | 2.05M | 625k | -8.14M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 4.28M | -9.36M | -8.17M | -10.22M | -8.99M |
| Investing | 954k | 770k | -413k | -329k | -390k |
| Financing | -4.55M | 6.16M | 10.21M | 12.11M | 7.14M |
| Market Cap | 9.98k |
| Price to Earnings Ratio | -0.46 |
| Price to Sales Ratio | 114.29 |
| Price to Cash Ratio | 4 |
| Price to Book Ratio | -0.98 |
| Dividend Yield | - |
| Shares Outstanding | 99.83M |
| Average Volume (1 week) | 22.66k |
| Average Volume (1 Month) | 66.7k |
| 52 Week Change | -99.72% |
| 52 Week High | 0.079 |
| 52 Week Low | 0.000001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Navidea Biopharmaceuticals Inc (CE) |
| Address |
838 walker road dover, delaware 19904 |
| Website | https://www.navidea.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
